Archives

Starting from trichlorosilane and silicon tetrachloride, Watson has established a complete technological framework for the silane industry, forming a three-tier product system of "basic raw materials → functional monomers → application derivatives," covering nine major functional categories.

Chiral catalysis plays a crucial role in fine chemicals and pharmaceutical synthesis. As a technology pioneer in this field, Watson Chem leverages years of technical expertise and innovation to provide global clients with highly efficient and reliable chiral catalysts and catalysis development services, helping them seamlessly transition from laboratory research to industrial-scale production.

In modern industrial applications, isooctanoates and neodecanoates are widely used across various industries due to their exceptional chemical stability and excellent solubility. These industries include resins, rubber catalysts, coatings and paint additives, driers, plastic heat stabilizers, and fuel combustion aids. As a leader in advanced chemical solutions, Watson has accumulated extensive technical expertise in these fields and continuously optimizes its production processes to provide high-quality products to global customers.

Watson possesses strong technical expertise in synthesizing organometallic compounds of transition metals (cobalt, manganese, copper, zinc, iron, nickel, chromium, zirconium, bismuth), alkali metals (lithium, sodium, potassium, strontium, barium, calcium, magnesium), rare earth metals (scandium, yttrium, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium), and noble metals (indium, gallium, gold, silver, antimony, hafnium, vanadium, titanium). This enables Watson to provide customized isooctanoate and neodecanoate products tailored to customer requirements.

GalNAc-L96 (CAS 1159408-62-4) is a triantennary GalNAc ligand that can be used for the synthesis of GalNAc-siRNA[1]. GalNAc is a ligand of ASGPR (asialoglycoprotein receptor). And Watson leverages cutting-edge glycochemistry and nucleic acid modification technologies to provide high-purity, high-quality GalNAc-L96 and its derivatives, ensuring optimal outcomes in RNAi and ASO drug development.